Suppr超能文献

乳腺癌辅助内分泌治疗患者中药物依从性原因量表简易中文版的跨文化调适

Cross-cultural adaptation of the simple Chinese version of the medication adherence reasons scale in patients undergoing adjuvant endocrine therapy for breast cancer.

作者信息

Xu Lei, Li Ping, Hu Yan, Xing Weijie, Qiu Jiajia, Zhang Xiaoju, Jia Lingying, Jing Feng, Liu Ye, Li Lili, Lu Chunyang

机构信息

Shanghai Evidence-Based Nursing Center, School of Nursing, Fudan University Centre for Evidence-Based Nursing: A Joanna Briggs Institute Centre of Excellence, Fudan University, NO. 305 Fenglin Road, Xuhui District, Shanghai, China.

Breast Surgery Department, Fudan University Shanghai Cancer Center, Shanghai, China.

出版信息

BMC Cancer. 2025 Jan 8;25(1):41. doi: 10.1186/s12885-024-13382-4.

Abstract

Adjuvant endocrine therapy (AET) is essential for improving survival and reducing mortality and recurrence rates in breast cancer (BrCa) patients. However, the adherence to AET among BrCa patients is poor, and there is no scale to measure adherence to AET or the reasons for non-adherence among BrCa patients in mainland China. The aim of this study was to assess the psychometric properties of the simple Chinese version of the Medication Adherence Reasons (MAR) scale in BrCa patients undergoing AET. This study utilized a cross-sectional research design with two phases: (1) translation and cross-cultural adaptation of the original English version of the MAR scale into simple Chinese and (2) validation of the simple Chinese version of the MAR scale (s-ChMAR scale) in BrCa patients. Instrument assessments included content validity, face validity, item analysis, construct validity, criterion-related validity and reliability testing. This study recruited participants using convenience sampling to investigate adherence to AET among BrCa patients. Inclusion criteria were: (a) female, (b) aged 18 years or older, (c) diagnosed with Stage I to III BrCa, (d) completed primary treatment for hormone receptor-positive BrCa and had been on AET for more than six months but less than five years, (e) proficient in Mandarin, and (f) provided informed consent. Exclusion criteria included psychiatric illness, cognitive impairment, or a diagnosis of another cancer type. The sample size for exploratory factor analysis (EFA) was determined based on a ratio of five to ten participants per scale item to ensure sufficient statistical power. Data were collected from a sample of 325 participants who received AET for over six months. All the items had a content validity index (CVI) of more than 0.80. Regarding construct validity, the s-ChMAR scale fit a four-dimensional model, the same as the original MAR scale tested in asthma patients. The s-ChMAR scale had good internal reliability (Cronbach's α = 0.896) and good stability (ICC = 0.837). In terms of quantifying non-adherence, the s-ChMAR scale identified a non-adherent participant rate of over 50%. The study findings support the reliability and validity of the s-ChMAR scale in measuring the non-adherence of Chinese BrCa patients to AET.

摘要

辅助内分泌治疗(AET)对于提高乳腺癌(BrCa)患者的生存率、降低死亡率和复发率至关重要。然而,BrCa患者对AET的依从性较差,在中国内地,尚无衡量BrCa患者对AET依从性或不依从原因的量表。本研究旨在评估接受AET的BrCa患者中简易中文版药物治疗依从性原因(MAR)量表的心理测量特性。本研究采用横断面研究设计,分为两个阶段:(1)将原始英文版MAR量表翻译并跨文化改编为简易中文版本;(2)在BrCa患者中验证简易中文版MAR量表(s-ChMAR量表)。工具评估包括内容效度、表面效度、项目分析、结构效度、效标关联效度和信度测试。本研究采用便利抽样招募参与者,以调查BrCa患者对AET的依从性。纳入标准为:(a)女性;(b)年龄18岁及以上;(c)诊断为I至III期BrCa;(d)完成激素受体阳性BrCa的初始治疗,且接受AET超过6个月但少于5年;(e)精通普通话;(f)提供知情同意书。排除标准包括精神疾病、认知障碍或诊断为其他癌症类型。探索性因子分析(EFA)的样本量根据每个量表项目5至10名参与者的比例确定,以确保有足够的统计效力。数据收集自325名接受AET超过6个月的参与者样本。所有项目的内容效度指数(CVI)均大于0.80。关于结构效度,s-ChMAR量表符合四维模型,与在哮喘患者中测试的原始MAR量表相同。s-ChMAR量表具有良好的内部信度(Cronbach's α = 0.896)和良好的稳定性(ICC = 0.837)。在量化不依从方面,s-ChMAR量表确定不依从参与者率超过50%。研究结果支持s-ChMAR量表在测量中国BrCa患者对AET不依从性方面的信度和效度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0026/11707837/8a4d95122afe/12885_2024_13382_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验